



The Overlooked Dimension of HIV Care: Public Health Strategies for Managing Hematologic Toxicities of Antiretroviral Therapy

***Emmanuel Ifeanyi Obeagu**

Department of Biomedical and Laboratory Science, Africa University, Zimbabwe.

*Corresponding author: Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe, emmanuelobeagu@yahoo.com,
ORCID: 0000-0002-4538-0161

Abstract

Antiretroviral therapy (ART) has revolutionized the management of Human Immunodeficiency Virus (HIV), transforming a once-fatal disease into a chronic, manageable condition. Despite these advances, hematologic toxicities associated with ART—including anemia, neutropenia, thrombocytopenia, and, in severe cases, pancytopenia—remain an often-overlooked dimension of HIV care. These adverse effects arise from a combination of direct bone marrow suppression, mitochondrial toxicity, immune-mediated destruction of blood cells, and metabolic disturbances, and they are exacerbated by coexisting infections, nutritional deficiencies, and drug interactions. Hematologic toxicities have profound implications for patient outcomes and public health. They compromise immune function, increase susceptibility to opportunistic infections, reduce adherence to ART, and elevate morbidity and mortality, particularly in resource-limited settings where laboratory monitoring and pharmacovigilance systems are inadequate. Routine hematologic assessment, nutritional interventions, and early detection of cytopenias are essential strategies to mitigate these risks. This narrative review synthesizes current evidence on the mechanisms, clinical manifestations, and public health consequences of ART-related hematologic toxicities. It also outlines evidence-based strategies to integrate hematologic monitoring into HIV programs, including strengthening laboratory capacity, promoting pharmacovigilance, implementing nutritional supplementation, and engaging communities in awareness and early reporting. Addressing hematologic complications through a comprehensive, multidisciplinary approach is critical for optimizing treatment efficacy, enhancing patient safety, and ensuring the long-term sustainability of ART programs.

Keywords: HIV, antiretroviral therapy, hematologic toxicity, public health, pharmacovigilance

Introduction

The global scale-up of antiretroviral therapy (ART) has transformed HIV infection from a fatal disease into a chronic, manageable condition, dramatically reducing AIDS-related morbidity and mortality. As of recent estimates, over 28 million people living with HIV (PLHIV) are receiving ART worldwide. However, alongside these clinical successes, the long-term administration of ART has revealed a spectrum of drug-related complications, with hematologic toxicities representing a particularly significant yet often overlooked dimension of care [1-3]. Hematologic abnormalities associated with ART—including anemia, neutropenia, thrombocytopenia, and pancytopenia—can profoundly impact patient outcomes. They compromise immune function, increase susceptibility to opportunistic infections, reduce adherence to therapy, and in severe cases, result in life-threatening complications. The pathophysiology of ART-related hematologic toxicity is multifactorial, encompassing direct bone marrow suppression, mitochondrial dysfunction, immune-mediated cell destruction, and metabolic disturbances. These mechanisms may be further exacerbated by nutritional deficiencies, coinfections such as tuberculosis or malaria, and polypharmacy, particularly in resource-limited settings [4-6].

Despite the clinical importance of these complications, hematologic toxicities remain underemphasized in public health strategies for HIV care. In many low- and middle-income countries (LMICs), inadequate laboratory infrastructure, limited pharmacovigilance systems, and insufficient healthcare worker training hinder timely detection and management. Consequently, patients often present with severe cytopenias or anemia only after significant clinical deterioration, leading to increased morbidity, treatment interruptions, and healthcare costs [7-10]. From a public health perspective, integrating hematologic monitoring and management into ART programs is essential. Routine assessment of hemoglobin, white blood cell counts, and platelet counts offers a cost-

effective, accessible, and reliable means of detecting early toxicities, optimizing ART regimens, and guiding supportive interventions such as nutritional supplementation and infection prevention. Moreover, strengthening pharmacovigilance systems and training healthcare personnel enhances early recognition and response to adverse events, improving treatment safety and adherence [11-12]. This narrative review explores the multifaceted nature of ART-induced hematologic toxicities, emphasizing both their pathophysiological mechanisms and public health implications. It highlights strategies to strengthen surveillance, clinical management, and community engagement, aiming to optimize ART outcomes and safeguard the health and well-being of PLHIV. Addressing hematologic toxicities as an integral component of HIV care is critical for sustaining long-term treatment success, reducing morbidity, and achieving equitable health outcomes globally.

Hematologic Toxicities of Antiretroviral Therapy

Hematologic toxicities are among the most frequently encountered complications of antiretroviral therapy (ART), yet they remain an underrecognized aspect of HIV management. These toxicities manifest across a spectrum of blood cell line abnormalities, including anemia, neutropenia, thrombocytopenia, and, in severe cases, pancytopenia. The incidence, severity, and clinical consequences of these abnormalities are influenced by the specific ART regimen, duration of therapy, patient comorbidities, and coexisting infections or nutritional deficiencies [13-14]. **Anemia** is the most commonly reported hematologic toxicity associated with ART. Nucleoside reverse transcriptase inhibitors (NRTIs), particularly zidovudine (AZT), are well-documented contributors to anemia. The drug exerts its effect through bone marrow suppression, mitochondrial toxicity, and impaired DNA synthesis in erythroid progenitor cells. Clinically, patients may present with fatigue, pallor, and reduced exercise tolerance. In resource-limited settings, where anemia is also common due to malnutrition or co-infections,

distinguishing drug-induced anemia from disease-related or environmental causes presents a significant challenge [15-17].

Neutropenia is another clinically relevant complication. It commonly arises from direct suppression of myeloid progenitor cells or immune-mediated destruction of neutrophils, often exacerbated by concomitant medications such as ganciclovir or cotrimoxazole. Neutropenia increases susceptibility to bacterial and fungal infections, posing a particular risk for patients with advanced immunosuppression. Early recognition is critical, as persistent neutropenia may necessitate dose adjustments, ART substitution, or the addition of granulocyte colony-stimulating agents [18-19]. **Thrombocytopenia** occurs less frequently but carries important clinical implications, particularly for bleeding risk. ART-induced thrombocytopenia may result from immune-mediated platelet destruction or impaired megakaryocyte maturation. Drugs implicated include zidovudine and certain protease inhibitors, though immune reconstitution following ART initiation may paradoxically exacerbate platelet reduction in some cases. Clinically, thrombocytopenia manifests as easy bruising, mucocutaneous bleeding, or, in severe cases, hemorrhagic complications [20-21].

In rare instances, **pancytopenia** can develop, reflecting profound bone marrow suppression. This severe manifestation is often multifactorial, involving direct drug toxicity, chronic inflammation, coexisting opportunistic infections, and nutritional deficiencies. Pancytopenia requires immediate clinical attention, as it significantly increases morbidity and can complicate ongoing ART therapy [22-23]. The mechanisms underlying ART-related hematologic toxicities are complex and interrelated. Mitochondrial dysfunction, immune-mediated cytotoxicity, drug interactions, and nutritional deficits collectively impair hematopoiesis. Importantly, these toxicities are often dose- and duration-dependent, with older NRTIs like zidovudine posing higher risk compared to newer agents such as tenofovir or dolutegravir [24-25]. Recognition of these toxicities is critical for effective HIV care. Routine monitoring of complete blood counts (CBC) provides a simple yet powerful tool for early detection and intervention. Adjustments to ART regimens, timely treatment of co-infections, and nutritional supplementation can mitigate the impact of hematologic abnormalities and preserve treatment efficacy (Table 1) [26-27].

Table 1. Common Antiretroviral Drugs and Associated Hematologic Toxicities

Drug/Class	Common Hematologic Toxicity	Mechanism of Action/Pathogenesis	Clinical Implications
Zidovudine (AZT) – NRTI	Macrocytic anemia, neutropenia	Bone marrow suppression via mitochondrial toxicity	Fatigue, immune suppression, opportunistic infections
Stavudine (d4T) – NRTI	Anemia, leukopenia	Mitochondrial dysfunction leading to cytopenia	Weakness, impaired ART adherence
Lamivudine (3TC) – NRTI	Rare anemia	Hypersensitivity, marrow suppression in combination therapy	Dose-dependent mild cytopenia
Nevirapine (NVP) – NNRTI	Eosinophilia, leukopenia	Hypersensitivity reaction, immune activation	Rash, liver injury, hematologic abnormalities
Lopinavir/Ritonavir – PI	Mild anemia	Bone marrow suppression, indirect hepatic metabolism effects	Usually transient, reversible
Tenofovir disoproxil fumarate	Minimal hematologic toxicity	Indirect effects through renal dysfunction	Rare anemia from erythropoietin deficiency

Pathophysiological Mechanisms of ART-Related Hematologic Toxicities

The development of hematologic toxicities in people living with HIV (PLHIV) on antiretroviral therapy (ART) is the result of complex, multifactorial mechanisms that involve direct pharmacologic effects, immune-mediated processes, and systemic metabolic disturbances. Understanding these mechanisms is essential for both clinical management and public health strategies aimed at minimizing morbidity and optimizing long-term therapy outcomes [28].

1. Bone Marrow Suppression

A primary mechanism of ART-induced hematologic toxicity is direct suppression of the bone marrow. Drugs such as zidovudine (AZT) and stavudine (d4T) interfere with DNA synthesis in erythroid, myeloid, and megakaryocyte progenitor cells. By inhibiting nuclear and mitochondrial DNA replication, these agents reduce the proliferation and differentiation of hematopoietic stem cells, resulting in anemia, neutropenia, and thrombocytopenia. In combination with chronic HIV-associated inflammation, this marrow suppression can be profound, sometimes leading to pancytopenia in advanced disease stages [29].

2. Mitochondrial Dysfunction

Nucleoside reverse transcriptase inhibitors (NRTIs) also induce mitochondrial toxicity, a key contributor to cytopenias. These drugs inhibit mitochondrial DNA polymerase γ , impairing oxidative phosphorylation and leading to accumulation of reactive oxygen species (ROS) within hematopoietic progenitors. Mitochondrial dysfunction disrupts energy-dependent cellular processes, induces apoptosis, and compromises red blood cell production, neutrophil function, and platelet formation. The cumulative effect of long-term mitochondrial injury increases vulnerability to hematologic toxicity, especially in patients with pre-existing nutritional deficiencies or co-infections [30].

3. Immune-Mediated Cytopenias

Immune dysregulation, a hallmark of HIV infection, can exacerbate ART-induced hematologic abnormalities. Certain drugs, particularly non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs), can trigger hypersensitivity reactions that lead to immune-mediated destruction of erythrocytes, leukocytes, or platelets. For example, autoantibody formation may precipitate anemia or thrombocytopenia, while immune reconstitution following ART initiation may paradoxically exacerbate cytopenias through heightened immune responses [31].

4. Nutritional and Metabolic Contributions

Nutritional deficiencies—particularly iron, folate, and vitamin B12 depletion—amplify ART-related hematologic toxicities. Deficiencies impair erythropoiesis and reduce the marrow's capacity to compensate for drug-induced suppression. ART-associated metabolic disturbances, such as mitochondrial-induced oxidative stress or altered lipid and glucose metabolism, further compromise marrow function. Chronic inflammation, common in HIV, also leads to elevated hepcidin levels, iron sequestration, and impaired red blood cell production, contributing to anemia of chronic disease [32].

5. Drug-Drug Interactions and Coinfections

ART rarely acts in isolation; many patients receive concurrent therapies for opportunistic infections such as tuberculosis, cytomegalovirus, or malaria. Medications like ganciclovir, cotrimoxazole, and rifampicin may compound marrow suppression or alter drug metabolism, heightening the risk of cytopenias. Coinfections themselves can infiltrate the marrow, disrupt erythropoiesis, or induce systemic inflammation, magnifying the hematologic impact of ART. Collectively, these mechanisms illustrate the interplay between pharmacologic toxicity, viral pathophysiology, immune dysregulation, and environmental factors in shaping hematologic outcomes among PLHIV. The multifactorial

nature of ART-related cytopenias underscores the importance of early detection, careful regimen selection, nutritional support, and routine laboratory monitoring to prevent severe complications and optimize treatment efficacy [33].

Public Health Implications of ART-Related Hematologic Toxicities

Hematologic toxicities of antiretroviral therapy (ART) extend beyond individual patient care, representing a significant public health concern, particularly in low- and middle-income countries (LMICs) where HIV prevalence is high and healthcare resources are constrained. These toxicities—ranging from mild anemia to severe pancytopenia—not only compromise patient safety but also influence treatment adherence, programmatic effectiveness, and overall health system efficiency (Table 2).

1. Impact on Treatment Outcomes

Anemia, neutropenia, and thrombocytopenia associated with ART can reduce tolerance to therapy, necessitate dose adjustments, or lead to treatment interruptions. Interruptions increase the risk of viral replication, immune deterioration, and development of drug-resistant strains of HIV. Consequently, hematologic toxicities indirectly threaten the effectiveness of ART programs and may contribute to suboptimal population-level outcomes [34].

2. Increased Susceptibility to Infections and Morbidity

Neutropenia and other cytopenias impair host immunity, heightening vulnerability to opportunistic infections such as tuberculosis, bacterial sepsis, and fungal infections. In regions with endemic infections like malaria, these hematologic complications exacerbate morbidity and strain public health services, as affected individuals are more likely to require hospitalization or specialized care [35].

3. Resource and Economic Implications

Hematologic toxicities increase healthcare utilization and costs due to additional laboratory tests, hospital admissions, supportive treatments, and management of opportunistic infections. In resource-limited settings, where laboratory infrastructure is often scarce, delayed detection of cytopenias can lead to severe complications, further burdening already overstretched health systems [36].

4. Opportunities for Surveillance and Early Intervention

From a public health perspective, integrating routine hematologic monitoring into ART programs offers an opportunity for early detection of toxicity, thereby reducing morbidity and improving adherence. Complete blood counts (CBCs), performed at baseline and periodically during therapy, provide a cost-effective method to identify emerging cytopenias. Coupled with pharmacovigilance systems, such monitoring allows health authorities to collect data on ART safety, inform policy adjustments, and optimize regimen selection for populations at risk [36].

5. Community Engagement and Education

Empowering patients to recognize and report symptoms of anemia or cytopenias—such as fatigue, pallor, recurrent infections, or bleeding tendencies—enhances early intervention and reduces complications. Health education programs, community-based monitoring, and counseling sessions can foster adherence and prompt care-seeking behavior, strengthening overall ART program effectiveness [37].

6. Integrated Public Health Strategies

Addressing ART-related hematologic toxicities requires an integrated approach that combines clinical management, nutritional support, infection control, and policy interventions. Nutritional supplementation programs targeting iron, folate, and vitamin B12 deficiencies can mitigate risk. Collaboration between HIV

programs, laboratory services, and pharmacovigilance networks ensures timely identification and management of adverse events,

while national guidelines incorporating routine hematologic surveillance provide a framework for sustainable public health interventions [38].

Table 2. Public Health Strategies for Managing ART-Related Hematologic Toxicities

Strategy	Implementation Approach	Expected Public Health Outcome
Routine hematologic monitoring	Integrate CBC testing into ART follow-up schedules	Early detection of toxicity; improved treatment safety
Nutritional support and supplementation	Provide iron, folate, and vitamin B12 through HIV clinics	Reduced incidence of anemia and cytopenias
Strengthening pharmacovigilance systems	Establish adverse drug reaction reporting mechanisms	Enhanced safety data and informed policy decisions
Capacity building for healthcare workers	Train clinicians and lab staff in toxicity identification	Improved case management and prevention
Community-based education and engagement	Empower patients to recognize and report hematologic symptoms	Early care-seeking behavior; reduced complications
Policy integration and health system linkage	Include hematologic surveillance in HIV national guidelines	Sustainable HIV care with lower morbidity rates

Policy and Programmatic Considerations

Effective management of hematologic toxicities associated with antiretroviral therapy (ART) requires coordinated policy and programmatic interventions that integrate clinical care, laboratory monitoring, pharmacovigilance, and community engagement. In many low- and middle-income countries (LMICs), where healthcare resources are limited, these toxicities can significantly undermine ART adherence, increase morbidity, and strain public health systems. Consequently, policies and programs must be designed to systematically address both individual patient needs and population-level outcomes [39]. National HIV treatment policies should explicitly include routine hematologic monitoring as part of standard care. Incorporating baseline and periodic complete blood counts (CBCs) and differential analyses into ART protocols allows early detection of anemia, neutropenia, and thrombocytopenia. Standardized guidelines promote uniform practices across health facilities, ensuring that patients at risk of cytopenias are identified and managed promptly [40].

Robust laboratory services are essential for detecting ART-related hematologic abnormalities. Policies should prioritize investment in laboratory equipment, reagents, and skilled personnel. Quality assurance programs and point-of-care testing technologies can further enhance diagnostic capacity, especially in rural or resource-constrained settings, enabling timely interventions before severe complications arise [41]. Systematic pharmacovigilance is critical for monitoring and mitigating ART-related hematologic toxicities. Policies should mandate reporting of adverse drug reactions, the development of national databases for real-time surveillance, and feedback mechanisms for clinicians. Such systems allow health authorities to identify high-risk populations, adjust ART regimens appropriately, and make data-driven decisions to optimize treatment safety [42]. Healthcare providers must be equipped with the knowledge and skills to recognize, manage, and report hematologic toxicities. Training programs should cover clinical signs of anemia, neutropenia, and thrombocytopenia, interpretation of laboratory results, and appropriate interventions including ART regimen modification, supportive therapy, and nutritional

supplementation. A well-trained workforce ensures adherence to standardized care protocols and enhances patient outcomes [43].

Policies should support integration of nutritional interventions into HIV programs, particularly supplementation of iron, folate, and vitamin B12 to mitigate ART-induced cytopenias. Linking ART services with community-based nutrition programs and food security initiatives can reduce the severity of hematologic toxicities, particularly in vulnerable populations such as children, pregnant women, and those with coinfections [44-45]. Engaging patients and communities in recognizing and reporting symptoms of hematologic toxicity is a vital programmatic strategy. Health education campaigns can increase awareness of warning signs such as fatigue, pallor, or unusual bleeding, encouraging timely healthcare-seeking behavior. Community involvement strengthens adherence to ART and enhances early detection of cytopenias, reducing preventable complications [46-47]. Policies should leverage laboratory, pharmacovigilance, and programmatic data to guide resource allocation and intervention strategies. Evidence-based decision-making enables targeted support for high-risk populations, informs ART regimen selection, and ensures sustainable implementation of hematologic monitoring programs [48-49]. By embedding these considerations into national HIV strategies, health systems can systematically reduce the burden of ART-induced hematologic toxicities, safeguard patient safety, and improve long-term treatment outcomes.

Conclusion

Hematologic toxicities of antiretroviral therapy (ART) represent a critical yet often overlooked dimension of HIV care. Conditions such as anemia, neutropenia, thrombocytopenia, and pancytopenia not only compromise immune function and increase susceptibility to opportunistic infections but also undermine treatment adherence and overall program effectiveness. The pathophysiology of these toxicities is multifactorial, involving direct bone

marrow suppression, mitochondrial dysfunction, immune-mediated cell destruction, nutritional deficiencies, and drug-drug interactions. From a public health perspective, addressing ART-related hematologic toxicities is essential to improving clinical outcomes and sustaining the long-term success of HIV programs. Integrating routine hematologic monitoring, strengthening laboratory and pharmacovigilance systems, implementing nutritional interventions, and promoting patient education are central to mitigating morbidity and enhancing treatment adherence. Community engagement and capacity building for healthcare workers further reinforce these efforts, ensuring timely detection, reporting, and management of cytopenias.

Policy frameworks must explicitly incorporate hematologic monitoring and management into national HIV strategies, emphasizing evidence-based approaches that are adaptable to resource-limited settings. By adopting a comprehensive, multidisciplinary approach that bridges clinical care, public health interventions, and policy implementation, health systems can reduce the burden of ART-induced hematologic complications, optimize therapeutic outcomes, and improve the quality of life for people living with HIV.

References

1. Kumah, E., Boakye, D. S., Boateng, R., & Agyei, E. (2023). Advancing the Global Fight Against HIV/Aids: Strategies, Barriers, and the Road to Eradication. *Annals of global health*, 89(1), 83. <https://doi.org/10.5334/aogh.4277>
2. Obeagu, E. I., & Obeagu, G. U. (2024). Impact of Maternal Eosinophils on Neonatal Immunity in HIV-Exposed Infants: A Review. *Elite Journal of Immunology*, 2(3), 1-18.
3. Obeagu, E. I., Ubosi, N. I., Obeagu, G. U., & Akram, M. (2024). Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*, 2(1), 52-61.

4. Duguma, N., Tesfaye Kiya, G., AdissuMaleko, W., &Bimerew, L. G. (2021). Hematological parameters abnormalities and associated factors in HIV-positive adults before and after highly active antiretroviral treatment in Goba Referral Hospital, southeast Ethiopia: A cross-sectional study. *SAGE open medicine*, 9, 20503121211020175. <https://doi.org/10.1177/20503121211020175>
5. Damtie, S., Workineh, L., Kiros, T., Eyayu, T., &Tiruneh, T. (2021). Hematological Abnormalities of Adult HIV-Infected Patients Before and After Initiation of Highly Active Antiretroviral Treatment at Debre Tabor Comprehensive Specialized Hospital, Northcentral Ethiopia: A Cross-Sectional Study. *HIV/AIDS (Auckland, N.Z.)*, 13, 477–484. <https://doi.org/10.2147/HIV.S308422>
6. Obeagu, E. I., &Obeagu, G. U. (2024). Platelet Aberrations in HIV Patients: Assessing Impacts of ART. *Elite Journal of Haematology*, 2(3), 10-24.
7. Obeagu, E. I., Obeagu, G. U., &Okwuanaso, C. B. (2024). Optimizing Immune Health in HIV Patients through Nutrition: A Review. *Elite Journal of Immunology*, 2(1), 14-33.
8. Moraleda, C., Aguilar, R., Quintó, L., Nhampossa, T., Renom, M., Nhabomba, A., Ruperez, M., Aponte, J. J., Achtman, A. H., Mañú Pereira, M. D. M., Schofield, L., Alonso, P. L., Macete, E., & Menéndez, C. (2021). Pathophysiology of Anemia in HIV-Infected Children Exposed to Malaria. *The American journal of tropical medicine and hygiene*, 104(3), 1003–1012. <https://doi.org/10.4269/ajtmh.19-0783>
9. Obeagu, E. I., &Obeagu, G. U. (2024). The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. *Elite Journal of Public Health*, 2(1), 35-51.
10. Obeagu, E. I., &Obeagu, G. U. (2024). Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences*, 4(1), 32-7.
11. Cao, G., Wang, Y., Wu, Y., Jing, W., Liu, J., & Liu, M. (2022). Prevalence of anemia among people living with HIV: A systematic review and meta-analysis. *EClinicalMedicine*, 44, 101283. <https://doi.org/10.1016/j.eclinm.2022.101283>
12. Shrivastav, V., M, Y., Ramachandran, A., Makwana, N., & Parmar, D. (2025). Prevalence and risk factors of anemia among people living with HIV/AIDS in Southeast Asia: a systematic review and meta-analysis. *BMC infectious diseases*, 25(1), 550. <https://doi.org/10.1186/s12879-025-10941-3>
13. Obeagu, E. I., &Obeagu, G. U. (2024). Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. *Journal home page: http://www. journalijiar. com*, 12(01).
14. Obeagu, E. I., Obeagu, G. U., Ede, M. O., Odo, E. O., & Buhari, H. A. (2023). Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine*, 102(49), e36599. <https://doi.org/10.1097/MD.00000000000036599>
15. Remien, R. H., Berkman, A., Myer, L., Bastos, F. I., Kagee, A., & El-Sadr, W. M. (2008). Integrating HIV care and HIV prevention: legal, policy and programmatic recommendations. *AIDS (London, England)*, 22 Suppl 2(Suppl 2), S57–S65. <https://doi.org/10.1097/01.aids.0000327437.13291.86>
16. Obeagu, E. I., Obeagu, G. U., Ukibe, N. R., &Oyebadejo, S. A. (2024). Anemia, iron, and HIV: decoding the interconnected pathways: A review. *Medicine*, 103(2), e36937. <https://doi.org/10.1097/MD.00000000000036937>
17. Ezechi, O., OdbergPettersson, K., &Byamugisha, J. (2012). HIV/AIDS, tuberculosis, and malaria in pregnancy. *Journal of pregnancy*, 2012, 140826. <https://doi.org/10.1155/2012/140826>
18. Yilma, A., Bailey, H., Karakousis, P. C., &Karanika, S. (2023). HIV/Tuberculosis Coinfection in Pregnancy and the Postpartum Period. *Journal of clinical medicine*, 12(19), 6302. <https://doi.org/10.3390/jcm12196302>
19. Obeagu, E. I., Obeagu, G. U., Ubosi, N. I., Uzoma, I. C., &Tayrab, E. M. A. (2024).

- Concurrent management of HIV and malaria: A comprehensive review of strategies to enhance quality of life. *Medicine*, 103(14), e37649.
<https://doi.org/10.1097/MD.00000000000037649>
20. Obeagu, E. I., &Obeagu, G. U. (2024). Platelet index ratios in HIV: Emerging biomarkers for immune health and disease management. *Medicine*, 103(12), e37576.
<https://doi.org/10.1097/MD.00000000000037576>
21. Damtie, S., Workineh, L., Kiros, T., Eyayu, T., &Tiruneh, T. (2021). Hematological Abnormalities of Adult HIV-Infected Patients Before and After Initiation of Highly Active Antiretroviral Treatment at Debre Tabor Comprehensive Specialized Hospital, Northcentral Ethiopia: A Cross-Sectional Study. *HIV/AIDS (Auckland, N.Z.)*, 13, 477–484.
<https://doi.org/10.2147/HIV.S308422>
22. Obeagu, E. I., Isiko, I., &Obeagu, G. U. (2025). Immunological factors influencing HIV acquisition in infants: A narrative review. *Medicine*, 104(25), e43039.
<https://doi.org/10.1097/MD.00000000000043039>
23. MandikiyanaChirimuta, L. A., Shamu, T., Chimbetete, C., & Part, C. (2024). Incidence and risk factors of anaemia among people on antiretroviral therapy in Harare. *Southern African journal of HIV medicine*, 25(1), 1605.
<https://doi.org/10.4102/sajhivmed.v25i1.1605>
24. Obeagu, E. I., &Obeagu, G. U. (2024). Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. *Medicine*, 103(9), e37354.
<https://doi.org/10.1097/MD.00000000000037354>
25. Boonyagars, L., Thinpangnga, P., &Munsakul, W. (2025). Incidence and Risk Factors of Zidovudine-Induced Anemia in Patients With HIV Infection Receiving Zidovudine-Containing Antiretroviral Therapy. *Journal of the International Association of Providers of AIDS Care*, 24, 23259582251321577.
<https://doi.org/10.1177/23259582251321577>
26. Dash, K. R., Meher, L. K., Hui, P. K., Behera, S. K., & Nayak, S. N. (2015). High Incidence of Zidovudine Induced Anaemia in HIV Infected Patients in Southern Odisha. *Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion*, 31(2), 247–250.
<https://doi.org/10.1007/s12288-014-0426-9>
27. Obeagu, E. I., Obeagu, G. U., &Akinleye, C. A. (2024). Unveiling the enigmatic roles of basophils in HIV infection: A narrative review. *Medicine*, 103(44), e40384.
<https://doi.org/10.1097/MD.00000000000040384>
28. Obeagu, E. I., &Obeagu, G. U. (2024). Preventive measures against HIV among Uganda's youth: Strategies, implementation, and effectiveness. *Medicine*, 103(44), e40317.
<https://doi.org/10.1097/MD.00000000000040317>
29. Shi, X., Sims, M. D., Hanna, M. M., Xie, M., Gulick, P. G., Zheng, Y. H., Basson, M. D., & Zhang, P. (2014). Neutropenia during HIV infection: adverse consequences and remedies. *International reviews of immunology*, 33(6), 511–536.
<https://doi.org/10.3109/08830185.2014.893301>
30. Nascimento, F. G., & Tanaka, P. Y. (2012). Thrombocytopenia in HIV-Infected Patients. *Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion*, 28(2), 109–111.
<https://doi.org/10.1007/s12288-011-0124-9>
31. Obeagu, E. I., &Goryacheva, O. G. (2025). Pancytopenia in HIV-positive patients with congestive heart failure: mechanisms, diagnosis, and treatment approaches. *Annals of medicine and surgery (2012)*, 87(9), 5624–5630.
<https://doi.org/10.1097/MS9.00000000000003501>
32. Aroca-Crevillén, A., Vicanolo, T., Ovadia, S., & Hidalgo, A. (2024). Neutrophils in Physiology and Pathology. *Annual review of pathology*, 19, 227–259.

- <https://doi.org/10.1146/annurev-pathmechdis-051222-015009>
33. Damtie, S., Workineh, L., Kiros, T., Eyayu, T., & Tiruneh, T. (2021). Hematological Abnormalities of Adult HIV-Infected Patients Before and After Initiation of Highly Active Antiretroviral Treatment at Debre Tabor Comprehensive Specialized Hospital, Northcentral Ethiopia: A Cross-Sectional Study. *HIV/AIDS (Auckland, N.Z.)*, 13, 477–484. <https://doi.org/10.2147/HIV.S308422>
34. Alexaki, A., & Wigdahl, B. (2008). HIV-1 infection of bone marrow hematopoietic progenitor cells and their role in trafficking and viral dissemination. *PLoS pathogens*, 4(12), e1000215. <https://doi.org/10.1371/journal.ppat.1000215>
35. John, M. T., Venter, M., Vaughan, J., Black, M., Prince, D., Luke, A. M., & John, M. (2022). Multiple opportunistic infections (pulmonary tuberculosis, *Mycobacterium avium* complex and parvovirus B19) in a single patient. *Southern African journal of HIV medicine*, 23(1), 1319. <https://doi.org/10.4102/sajhivmed.v23i1.1319>
36. Obeagu, E. I., & Obeagu, G. U. (2025). Anemia and cerebrovascular disease: pathophysiological insights and clinical implications. *Annals of medicine and surgery* (2012), 87(6), 3254–3267. <https://doi.org/10.1097/MS9.00000000000002907>
37. Ferede, G., & Wondimeneh, Y. (2013). Prevalence and related factors of anemia in HAART-naïve HIV positive patients at Gondar University Hospital, Northwest Ethiopia. *BMC hematology*, 13(1), 8. <https://doi.org/10.1186/2052-1839-13-8>
38. Abioye, A. I., Sudfeld, C. R., Noor, R. A., Ulenga, N., Sando, D., & Fawzi, W. W. (2024). Anemia and Iron Supplementation in Relation to Viral Load and Mortality among 70,442 People Living with Human Immunodeficiency Virus in Tanzania. *The Journal of nutrition*, 154(6), 1927–1935. <https://doi.org/10.1016/j.tjnut.2024.04.019>
39. Sahu, K. K., Mishra, A. K., Lal, A., & Abraham, G. M. (2019). *Mycobacterium Avium* Complex: A Rare Cause of Pancytopenia in HIV Infection. *Journal of microscopy and ultrastructure*, 8(1), 27–30. https://doi.org/10.4103/JMAU.JMAU_18_19
40. Sanyaolu, A. O., Fagbenro-Beyioku, A. F., Oyibo, W. A., Badaru, O. S., Onyeabor, O. S., & Nnaemeka, C. I. (2013). Malaria and HIV co-infection and their effect on haemoglobin levels from three health-care institutions in Lagos, southwest Nigeria. *African health sciences*, 13(2), 295–300. <https://doi.org/10.4314/ahs.v13i2.14>
41. Broder S. (2010). The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. *Antiviral research*, 85(1), 1–18. <https://doi.org/10.1016/j.antiviral.2009.10.002>
42. Hruz P. W. (2008). HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models. *Current opinion in HIV and AIDS*, 3(6), 660–665. <https://doi.org/10.1097/COH.0b013e3283139134>
43. Schank, M., Zhao, J., Moorman, J. P., & Yao, Z. Q. (2021). The Impact of HIV- and ART-Induced Mitochondrial Dysfunction in Cellular Senescence and Aging. *Cells*, 10(1), 174. <https://doi.org/10.3390/cells10010174>
44. Simo, J. L., Tuono, R. M., Manewa, B. T., Seuko, M. N., Matchein, Y. N., & Tayou, C. T. (2025). Cytopenias and Associated Factors in Patients Living With HIV on ARV Treatment in Cameroon: An Analytical Cross-Sectional Study. *Advances in hematology*, 2025, 3328539. <https://doi.org/10.1155/ah/3328539>
45. Katemba, C., Muzoora, C., Muwanguzi, E., Mwambi, B., Atuhairwe, C., & Taremwa, I. M. (2018). Hematological abnormalities in HIV-antiretroviral therapy naïve clients as seen at an immune suppression syndrome clinic at Mbarara Regional Referral Hospital, southwestern Uganda. *Journal of blood medicine*, 9, 105–110. <https://doi.org/10.2147/JBM.S157148>
46. Bhardwaj, S., Almaen, A., Ahmed Wani, F., & Thirunavukkarasu, A. (2020). Hematologic derangements in HIV/AIDS patients and their relationship with the CD4 counts: a cross-sectional study. *International journal of*

clinical and experimental pathology, 13(4), 756–763.

47. Aynalem, Y. A., Shibabaw Shiferaw, W., & Woldiye, Z. (2020). Prevalence of Anemia and Its Associated Factors in Antiretroviral-Treated HIV/AIDS-Positive Adults from 2013 to 2018 at Debre Berhan Referral Hospital, Ethiopia. *Advances in hematology*, 2020, 2513578.
<https://doi.org/10.1155/2020/2513578>
48. Patange, A. P., Desai, J. V., Pujari, B., Marwah, A., & Dey, A. (2024). Dynamic Assessment of Hematological Parameters as Predictive Biomarkers for Disease Severity and Prognosis in COVID-19 Patients: A Longitudinal Study. *Cureus*, 16(7), e63593.
<https://doi.org/10.7759/cureus.63593>
49. Modlin, C. E., Naburi, H., Hendricks, K. M., Lyatuu, G., Kimaro, J., Adams, L. V., Palumbo, P. E., & von Reyn, C. F. (2014). Nutritional Deficiencies and Food Insecurity Among HIV-infected Children in Tanzania. *International journal of MCH and AIDS*, 2(2), 220–228.

Access this Article in Online	
	Website: www.ijcrims.com
	Subject: Haematology
Quick Response Code	
DOI: 10.22192/ijcrms.2025.11.10.005	

How to cite this article:

Emmanuel Ifeanyi Obeagu. (2025). The Overlooked Dimension of HIV Care: Public Health Strategies for Managing Hematologic Toxicities of Antiretroviral Therapy. *Int. J. Curr. Res. Med. Sci.* 11(10): 39-49.

DOI: <http://dx.doi.org/10.22192/ijcrms.2025.11.10.005>